Ebina T, Kohya H, Inoue H, Aso H
Gan To Kagaku Ryoho. 1987 Jun;14(6 Pt 1):1841-6.
After oral administration of 20 mg/kg of PSK, a significant level of interferon (IFN) activity was detected in the sera of BCG (1 mg/mouse)-sensitized mice. A low titer of IFN was also detected in the sera of all of 4 cancer patients after 3 g/day oral administration of PSK for 7 consecutive days. Intratumoral administration of PSK (5 mg/mouse) strongly inhibited the growth of Meth-A solid tumors in male BALB/c mice and led to complete regression of tumors and resistance to reinoculated tumors in the host animals. Subsequently, the antimetastatic effect of PSK was examined in a "double grafted tumor system" in which mice first received simultaneous intradermal inoculations of Meth-A in the right (10(6) cells) and left (2 X 10(5) cells) flanks and were then injected with PSK in the right tumor on day 3. PSK significantly inhibited the growth of the left, non-treated tumor. When mice received an inoculation of Meth-A (2 X 10(5) cells) in the left flank and PSK was injected subcutaneously in the right flank on day 3 (single tumor system), the growth of the tumor was not inhibited. These findings suggest that intratumoral PSK immunotherapy in one region has an effect on tumor growth in another region.
口服给予20mg/kg的PSK后，在卡介苗（1mg/小鼠）致敏的小鼠血清中检测到显著水平的干扰素（IFN）活性。连续7天每天口服3g的PSK后，在4例癌症患者的血清中也检测到低滴度的IFN。向雄性BALB/c小鼠瘤内注射PSK（5mg/小鼠）可强烈抑制Meth-A实体瘤的生长，并导致肿瘤完全消退以及宿主动物对再次接种肿瘤产生抗性。随后，在“双移植瘤系统”中检测PSK的抗转移作用，在该系统中，小鼠首先在右侧（10⁶个细胞）和左侧（2×10⁵个细胞）胁腹同时进行Meth-A皮内接种，然后在第3天在右侧肿瘤中注射PSK。PSK显著抑制了左侧未处理肿瘤的生长。当小鼠在左侧胁腹接种Meth-A（2×10⁵个细胞）并在第3天在右侧胁腹皮下注射PSK（单肿瘤系统）时，肿瘤生长未受抑制。这些发现表明，在一个区域进行瘤内PSK免疫治疗对另一个区域的肿瘤生长有影响。
